このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Neuren Pharmaceuticals バランスシートの健全性

財務の健全性基準チェック /66

Neuren Pharmaceuticalsの総株主資本はA$205.2M 、総負債はA$0.0で、負債比率は0%となります。総資産と総負債はそれぞれA$248.0MとA$42.8Mです。 Neuren Pharmaceuticalsの EBIT はA$199.2Mで、利息カバレッジ比率-35です。現金および短期投資はA$228.5Mです。

主要情報

負債資本比率

AU$0

負債

インタレスト・カバレッジ・レシオ	-35x
現金	AU$228.54m
エクイティ	AU$205.21m
負債合計	AU$42.76m
総資産	AU$247.97m

財務の健全性に関する最新情報

更新なし

Recent updates

財務状況分析

短期負債: NEUの短期資産 ( A$247.2M ) が短期負債 ( A$42.8M ) を超えています。

長期負債: NEUには長期負債はありません。

デット・ツー・エクイティの歴史と分析

負債レベル: NEUは負債がありません。

負債の削減: NEU過去 5 年間負債を抱えていません。

債務返済能力: NEUには負債がないため、営業キャッシュフローでカバーする必要はありません。

インタレストカバレッジ: NEUには負債がないため、利息支払いの負担は問題になりません。

Neuren Pharmaceuticals バランスシートの健全性

財務の健全性 基準チェック /66

主要情報

財務の健全性に関する最新情報

Recent updates

Investor sentiment improves as stock rises 16%

Neuren Phase 2 Trial Shows Significant Improvements in Pitt Hopkins Syndrome

Neuren Pharmaceuticals Limited, Annual General Meeting, May 28, 2024

Neuren Pharmaceuticals Limited to Report Q4, 2023 Results on Feb 29, 2024

Investor sentiment improves as stock rises 38%

Investor sentiment improves as stock rises 20%

Now 23% undervalued after recent price drop

Now 20% undervalued after recent price drop

Now 25% undervalued after recent price drop

Neuren Pharmaceuticals Limited Reiterates Net Sales Guidance for the Third Quarter of 2023

Neuren Pharmaceuticals Limited to Report First Half, 2023 Results on Aug 28, 2023

Now 21% undervalued

Independent Non-Executive Director recently sold AU$15m worth of stock

Neuren Pharmaceuticals Limited Announces Prader-Willi Syndrome IND for NNZ-2591 Approval by FDA

Neuren Pharmaceuticals Submits Investigational New Drug & First Patients Complete Phase 2 Trials

Neuren Pharmaceuticals Reports Rett Syndrome New Drug Application Accepted for Priority Review by US Food and Drug Administration

Neuren Pharmaceuticals Limited Commences Phase 2 Trials of NNZ-2591 in PMS and PTHS

Neuren Pharmaceuticals Limited Commences Phase 2 Trial of NNZ-2591 in Angelman

Neuren Pharmaceuticals Appoints Liza A. Squires as Chief Medical Officer in United States

Forecast breakeven date pushed back to 2023

Forecast breakeven date pushed back to 2023

Neuren Pharmaceuticals Limited Receives FDA Approval for Angelman IND and Phase 2 Trial

Independent Non-Executive Director recently bought AU$59k worth of stock

Neuren Pharmaceuticals Submits Investigational New Drug Application to the US Food and Drug Administration for NNZ-2591

Neuren Pharmaceuticals Limited announced that it expects to receive AUD 20.000001 million in funding

Neuren Pharmaceuticals Limited Submits an Investigational New Drug (IND) Application to the US Food and Drug Administration (FDA) for NNZ-2591 to Treat Angelman Syndrome

High number of new directors

Independent Non-Executive Chairman recently bought AU$61k worth of stock

Neuren Pharmaceuticals Limited Receives Clear and Constructive Guidance from the Fda Office of Neuroscience in preIND Meetings for Phase 2 Clinical Trials of Nnz2591

Neuren Successfully Completes Drug Substance Manufacturing for NNZ-2591 Phase 2 Trials

New 90-day low: AU$1.26

Full year 2020 earnings released: AU$0.086 loss per share (vs AU$0.11 loss in FY 2019)

Independent Non-Executive Chairman recently bought AU$50k worth of stock

Neuren Pharmaceuticals Limited Adds Prader-Willi Syndrome to Pipeline with Compelling Results for NNZ-2591 in Pre-Clinical Model

European Commission Grants 3 NNZ-2591 Orphan Designations to Neuren Pharmaceuticals

New 90-day high: AU$1.40

Neuren Pharmaceuticals Limited Receives Approval for Final Stage of NNZ-2591 Clinical Trial

New 90-day high: AU$1.30

New 90-day low: AU$1.06

New 90-day low: AU$1.10

財務状況分析

デット・ツー・エクイティの歴史と分析

貸借対照表

健全な企業の発掘

財務の健全性基準チェック /66